Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 329.55 INR -1.91% Market Closed
Market Cap: 394.7B INR
Have any thoughts about
Biocon Ltd?
Write Note

Biocon Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocon Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Biocon Ltd
NSE:BIOCON
Total Equity
â‚ą197.8B
CAGR 3-Years
36%
CAGR 5-Years
25%
CAGR 10-Years
20%
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Total Equity
â‚ą787.1m
CAGR 3-Years
71%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Transgene Biotek Ltd
BSE:526139
Total Equity
â‚ą108.3m
CAGR 3-Years
-14%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Total Equity
â‚ą931.7m
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Hester Biosciences Ltd
NSE:HESTERBIO
Total Equity
â‚ą3B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Panacea Biotec Ltd
NSE:PANACEABIO
Total Equity
â‚ą8.3B
CAGR 3-Years
N/A
CAGR 5-Years
24%
CAGR 10-Years
N/A
No Stocks Found

Biocon Ltd
Glance View

Market Cap
395.7B INR
Industry
Biotechnology

In the bustling world of biotechnology, Biocon Ltd. stands as a beacon of innovation, rooted in its Indian origins yet extending its influence globally. Founded in 1978 by Kiran Mazumdar-Shaw, a visionary with a degree in fermentation science, Biocon began its journey as a maker of enzymes before transforming into a formidable force in biopharmaceuticals. This transformation was driven by the company's emphasis on research and development, leading to groundbreaking advancements in biosimilars, generics, and novel biotherapeutics. These products cater to critical areas such as oncology, diabetes, and autoimmune diseases. The company's success hinges on its ability to blend scientific rigor with entrepreneurial flair, enabling it to deliver high-quality, cost-effective solutions in a market traditionally dominated by Western giants. Biocon's revenue model is intricately woven from various strands of its expansive portfolio. A significant chunk emerges from its biologics division, where it manufactures biosimilars that serve as cost-friendly alternatives to expensive biologic drugs. Simultaneously, the company capitalizes on its expertise in small molecule APIs and branded formulations, which are integral to its generics business. Furthermore, collaborations and partnerships with global pharmaceutical companies amplify its reach, facilitating market access and regulatory navigation. Through these strategic undertakings, Biocon not only bolsters its financial performance but also reinforces its commitment to enhancing healthcare affordability and accessibility across the globe.

BIOCON Intrinsic Value
414.66 INR
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Biocon Ltd's Total Equity?
Total Equity
197.8B INR

Based on the financial report for Sep 30, 2024, Biocon Ltd's Total Equity amounts to 197.8B INR.

What is Biocon Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
20%

Over the last year, the Total Equity growth was 4%. The average annual Total Equity growth rates for Biocon Ltd have been 36% over the past three years , 25% over the past five years , and 20% over the past ten years .

Back to Top